These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 20826182)

  • 21. A phase II study of plerixafor (AMD3100) plus G-CSF for autologous hematopoietic progenitor cell mobilization in patients with Hodgkin lymphoma.
    Cashen A; Lopez S; Gao F; Calandra G; MacFarland R; Badel K; DiPersio J
    Biol Blood Marrow Transplant; 2008 Nov; 14(11):1253-61. PubMed ID: 18940680
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New agents for mobilizing peripheral blood stem cells.
    Greinix HT; Worel N
    Transfus Apher Sci; 2009 Aug; 41(1):67-71. PubMed ID: 19615944
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma.
    DiPersio JF; Micallef IN; Stiff PJ; Bolwell BJ; Maziarz RT; Jacobsen E; Nademanee A; McCarty J; Bridger G; Calandra G;
    J Clin Oncol; 2009 Oct; 27(28):4767-73. PubMed ID: 19720922
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In and out of the niche: perspectives in mobilization of hematopoietic stem cells.
    Mohty M; Ho AD
    Exp Hematol; 2011 Jul; 39(7):723-9. PubMed ID: 21624427
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A combination of granulocyte-colony-stimulating factor (G-CSF) and plerixafor mobilizes more primitive peripheral blood progenitor cells than G-CSF alone: results of a European phase II study.
    Fruehauf S; Veldwijk MR; Seeger T; Schubert M; Laufs S; Topaly J; Wuchter P; Dillmann F; Eckstein V; Wenz F; Goldschmidt H; Ho AD; Calandra G
    Cytotherapy; 2009; 11(8):992-1001. PubMed ID: 19929463
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The high-affinity CXCR4 antagonist BKT140 is safe and induces a robust mobilization of human CD34+ cells in patients with multiple myeloma.
    Peled A; Abraham M; Avivi I; Rowe JM; Beider K; Wald H; Tiomkin L; Ribakovsky L; Riback Y; Ramati Y; Aviel S; Galun E; Shaw HL; Eizenberg O; Hardan I; Shimoni A; Nagler A
    Clin Cancer Res; 2014 Jan; 20(2):469-79. PubMed ID: 24246358
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment with plerixafor in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient.
    Stiff P; Micallef I; McCarthy P; Magalhaes-Silverman M; Weisdorf D; Territo M; Badel K; Calandra G
    Biol Blood Marrow Transplant; 2009 Feb; 15(2):249-56. PubMed ID: 19167685
    [TBL] [Abstract][Full Text] [Related]  

  • 28. GPC-100, a novel CXCR4 antagonist, improves in vivo hematopoietic cell mobilization when combined with propranolol.
    Sukhtankar DD; Fung JJ; Kim MN; Cayton T; Chiou V; Caculitan NG; Zalicki P; Kim S; Jo Y; Kim S; Lee JM; Choi J; Mun S; Chin A; Jang Y; Lee JY; Kim G; Kim EH; Huh WK; Jeong JY; Seen DS; Cardarelli PM
    PLoS One; 2023; 18(10):e0287863. PubMed ID: 37878624
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Plerixafor enables successful hematopoietic stem cell collection in an extensively pretreated patient with testicular cancer.
    Saure C; Weigelt C; Schroeder T; Klärner V; Galonska L; Haas R; Kobbe G
    Acta Haematol; 2010; 124(4):235-8. PubMed ID: 21099212
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Blood graft lymphocyte subsets after plerixafor injection in non-Hodgkin's lymphoma patients mobilizing poorly with chemotherapy plus granulocyte-colony-stimulating factor.
    Varmavuo V; Mäntymaa P; Kuittinen T; Nousiainen T; Jantunen E
    Transfusion; 2012 Aug; 52(8):1785-91. PubMed ID: 22304442
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structural analogues of AMD3100 mobilise haematopoietic progenitor cells from bone marrow in vivo according to their ability to inhibit CXCL12 binding to CXCR4 in vitro.
    Martin C; Bridger GJ; Rankin SM
    Br J Haematol; 2006 Aug; 134(3):326-9. PubMed ID: 16787495
    [TBL] [Abstract][Full Text] [Related]  

  • 32. AMD3100 mobilizes hematopoietic stem cells with long-term repopulating capacity in nonhuman primates.
    Larochelle A; Krouse A; Metzger M; Orlic D; Donahue RE; Fricker S; Bridger G; Dunbar CE; Hematti P
    Blood; 2006 May; 107(9):3772-8. PubMed ID: 16439684
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma.
    Stewart DA; Smith C; MacFarland R; Calandra G
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):39-46. PubMed ID: 19135941
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Plerixafor in poor stem cell mobilizers: the Belgian Compassionate Use Program.
    Selleslag D; Dierickx D; Breems DA; Huynh P; Van De Velde A; Meers S; Brouwer E; Mertens A
    Acta Clin Belg; 2011; 66(3):200-4. PubMed ID: 21837928
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CXCR4 and mobilization of hematopoietic precursors.
    Rettig MP; Ramirez P; Nervi B; DiPersio JF
    Methods Enzymol; 2009; 460():57-90. PubMed ID: 19446720
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Concurrent blockade of alpha4-integrin and CXCR4 in hematopoietic stem/progenitor cell mobilization.
    Bonig H; Watts KL; Chang KH; Kiem HP; Papayannopoulou T
    Stem Cells; 2009 Apr; 27(4):836-7. PubMed ID: 19350684
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Functional potentials of human hematopoietic progenitor cells are maintained by mesenchymal stromal cells and not impaired by plerixafor.
    Ludwig A; Saffrich R; Eckstein V; Bruckner T; Wagner W; Ho AD; Wuchter P
    Cytotherapy; 2014 Jan; 16(1):111-21. PubMed ID: 24119647
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mobilization of hematopoietic stem cells into the peripheral blood.
    Damon LE; Damon LE
    Expert Rev Hematol; 2009 Dec; 2(6):717-33. PubMed ID: 21082960
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Plerixafor (Mozobil) alone to mobilize hematopoietic stem cells from multiple myeloma patients for autologous transplantation.
    Flomenberg N; Comenzo RL; Badel K; Calandra G
    Biol Blood Marrow Transplant; 2010 May; 16(5):695-700. PubMed ID: 20067838
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BIO5192, a small molecule inhibitor of VLA-4, mobilizes hematopoietic stem and progenitor cells.
    Ramirez P; Rettig MP; Uy GL; Deych E; Holt MS; Ritchey JK; DiPersio JF
    Blood; 2009 Aug; 114(7):1340-3. PubMed ID: 19571319
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.